Explore how the FRAXA Drug Validation Initiative is revolutionizing Fragile X syndrome treatment, leading the charge towards innovative therapies and hope for affected families.
Read moreDeacon, Robert
FRAXA Drug Validation Initiative (FRAXA-DVI)
![FRAXA Drug Validation Initiative (FRAXA-DVI) FRAXA-DVI laboratory](https://www.fraxa.org/wp-content/uploads/2019/04/fotolia_36759360_alexander_raths-e1617982764430-720x300.jpg)
The FRAXA Drug Validation Initiative (FRAXA-DVI) provides speedy, cost-effective, objective preclinical testing of potential Fragile X treatments. FRAXA-DVI uses in-vitro systems, behavior batteries, and gene expression and peripheral biomarker platforms to validate investigational new drugs and repurposed available compounds in Fragile X syndrome (FXS).
Read more